Electromagnetic Field Protection Device Use Impact in Healthy Volunteers
Clinical and Molecular Impact of In-home Resonance-based Electromagnetic Field Protection Device Usage in Healthy Individuals
1 other identifier
interventional
44
0 countries
N/A
Brief Summary
This is a prospective, single group, self-controlled study to evaluate the clinical and molecular impact of continuous in-home resonance-based electromagnetic field (EMF) protection device usage in healthy individuals.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_2
Started Mar 2022
Shorter than P25 for phase_2
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 27, 2021
CompletedFirst Posted
Study publicly available on registry
August 12, 2021
CompletedStudy Start
First participant enrolled
March 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2023
CompletedMarch 14, 2022
March 1, 2022
10 months
July 27, 2021
March 10, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Epigenetic Testing
Change from baseline to 12 weeks
Study Arms (1)
In-home EMF protection device
EXPERIMENTALInterventions
Participants will have an in-home EMF protection device
Eligibility Criteria
You may qualify if:
- Any sex, gender orientation, and ethnicity
- Between ages 30 and 70
- Must be willing and able to participate in venipuncture, health history and clinical assessments, passive monitoring (Oura ring), and continuous in-home Blushield device usage
You may not qualify if:
- Significant change in diagnosis and/or treatment of major illness or injury within 2 years prior to screening, e.g., diabetes, cancer, cardiovascular disease, psychiatric condition 2. Any ongoing immune system concerns or immunodeficiency disease
- History of any viral illness in preceding year
- Body mass index (BMI) \> 35 kg/m2
- Presence of active infection
- Any other illness, disorder, alcohol or chemical dependence that in the opinion of investigators would render study participation unsuitable
- Unable or unwilling to provide required biological sample
- Unable or unwilling to avoid pregnancy during study period
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- TruDiagnosticlead
- Blushield USAcollaborator
Related Publications (3)
Hernandez-Segura A, Nehme J, Demaria M. Hallmarks of Cellular Senescence. Trends Cell Biol. 2018 Jun;28(6):436-453. doi: 10.1016/j.tcb.2018.02.001. Epub 2018 Feb 21.
PMID: 29477613BACKGROUNDKaripidis K, Mate R, Urban D, Tinker R, Wood A. 5G mobile networks and health-a state-of-the-science review of the research into low-level RF fields above 6 GHz. J Expo Sci Environ Epidemiol. 2021 Jul;31(4):585-605. doi: 10.1038/s41370-021-00297-6. Epub 2021 Mar 16.
PMID: 33727687BACKGROUNDKohli J, Wang B, Brandenburg SM, Basisty N, Evangelou K, Varela-Eirin M, Campisi J, Schilling B, Gorgoulis V, Demaria M. Algorithmic assessment of cellular senescence in experimental and clinical specimens. Nat Protoc. 2021 May;16(5):2471-2498. doi: 10.1038/s41596-021-00505-5. Epub 2021 Apr 28.
PMID: 33911261BACKGROUND
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 27, 2021
First Posted
August 12, 2021
Study Start
March 1, 2022
Primary Completion
January 1, 2023
Study Completion
April 1, 2023
Last Updated
March 14, 2022
Record last verified: 2022-03